TL;DR: Arpeggio Bio is a Y Combinator Summer 2019 startup develops drugs targeting transcription factors using AI…, currently active with a team of 20.
Arpeggio Bio develops drugs targeting transcription factors using AI…
Last verified:
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Built by LemStudio
Yes. Arpeggio Bio was funded by Y Combinator in the Summer 2019 batch. Arpeggio Bio develops drugs targeting transcription factors using AI…
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment…
Arpeggio Bio was part of Y Combinator's Summer 2019 batch.
Arpeggio Bio has a team of 20 people according to Y Combinator's directory.
Arpeggio Bio is currently listed as Active with a team of 20 in Y Combinator's directory.
Loading interactive view…